Vesa Hongisto
Vesa Hongisto has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Pekka Kohonen
Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
3 shared publications - Penny Nymark
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
2 shared publications - Roland C. Grafström
Misvik Biology Oy, Karjakatu 35 20520 Turku, Finland
2 shared publications - Roland Grafström
Karolinska Institutet Institute of Environmental Medicine Nobels väg 13 171 77 Stockholm Sweden
2 shared publications Amaia García‐Bilbao
GAIKER Technology Centre Parque Tecnológico Ed. 202 48170 Zamudio Bizkaia Spain
1 shared publication- Andrew Nelson
School of Chemistry, University of Leeds, Leeds LS2 9JT, UK
1 shared publication
Latest Publications
- Open Access
- 1 February 2025
- Published by Elsevier in Bioelectrochemistry
- Vol. 164, 108927
Emerging screening platform characterises aminoquinoline structure–activity relationships with phospholipid layers
- 1 February 2025
- Published by Elsevier in Bioelectrochemistry
- Vol. 164, 108927
Open AccessEmerging screening platform characterises aminoquinoline structure–activity relationships with phospholipid layers
Toward Rigorous Materials Production: New Approach Methodologies Have Extensive Potential to Improve Current Safety Assessment Practices
Advanced material development, including at the nanoscale, comprises costly and complex challenges coupled to ensuring human and environmental safety. Governmental agencies regulating safety have announced interest toward acceptance of safety data generated under the collective term New Approach Methodologies (NAMs), as such technologies/approaches offer marked potential to progress the integration of safety testing measures during innovation from idea to product launch of nanomaterials. Divided in overall eight main categories, searchable databases for grouping and read across purposes, exposure assessment and modeling, in silico modeling of physicochemical structure and hazard data, in vitro high‐throughput and high‐content screening assays, dose‐response assessments and modeling, analyses of biological processes and toxicity pathways, kinetics and dose extrapolation, consideration of relevant exposure levels and biomarker endpoints typify such useful NAMs. Their application generally agrees with articulated stakeholder needs for improvement of safety testing procedures. They further fit for inclusion and add value in nanomaterials risk assessment tools. Overall 37 of 50 evaluated NAMs and tiered workflows applying NAMs are recommended for considering safer‐by‐design innovation, including guidance to the selection of specific NAMs in the eight categories. An innovation funnel enriched with safety methods is ultimately proposed under the central aim of promoting rigorous nanomaterials innovation.
Toward Rigorous Materials Production: New Approach Methodologies Have Extensive Potential to Improve Current Safety Assessment Practices
Advanced material development, including at the nanoscale, comprises costly and complex challenges coupled to ensuring human and environmental safety. Governmental agencies regulating safety have announced interest toward acceptance of safety data generated under the collective term New Approach Methodologies (NAMs), as such technologies/approaches offer marked potential to progress the integration of safety testing measures during innovation from idea to product launch of nanomaterials. Divided in overall eight main categories, searchable databases for grouping and read across purposes, exposure assessment and modeling, in silico modeling of physicochemical structure and hazard data, in vitro high‐throughput and high‐content screening assays, dose‐response assessments and modeling, analyses of biological processes and toxicity pathways, kinetics and dose extrapolation, consideration of relevant exposure levels and biomarker endpoints typify such useful NAMs. Their application generally agrees with articulated stakeholder needs for improvement of safety testing procedures. They further fit for inclusion and add value in nanomaterials risk assessment tools. Overall 37 of 50 evaluated NAMs and tiered workflows applying NAMs are recommended for considering safer‐by‐design innovation, including guidance to the selection of specific NAMs in the eight categories. An innovation funnel enriched with safety methods is ultimately proposed under the central aim of promoting rigorous nanomaterials innovation.
- 1 April 2018
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 15 (Supplement) , S91-S97
Toxic and Genomic Influences of Inhaled Nanomaterials as a Basis for Predicting Adverse Outcome
An immense variety of different types of engineered nanomaterials are currently being developed and increasingly applied to consumer products. Importantly, engineered nanomaterials may pose unexplored adverse health effects because of their small size. Particularly in occupational settings, the dustiness of certain engineered nanomaterials involves risk of inhalation and influences on lung function. These facts call for quick and cost-effective safety testing practices, such as that obtained through multiparametric high-throughput screening using cultured human lung cells. The predictive value of such in vitro–based testing depends partly on the effectiveness of coverage of the mechanisms underlying toxicity effects. The concept of adverse outcome pathways covers the array of causative effects starting from a molecular initiating event via cellular-, organ-, individual-, and population-level effects. Screening for adverse outcome pathway–related effects that drive the eventual toxic outcome provides a good basis for developing predictive testing methods and data-driven integrated testing strategies for hazard and risk assessment. Temporal and inherited genomic changes are likely to drive many adverse responses to engineered nanomaterials, such as multiwalled carbon nanotubes, of which one specific form has recently been evaluated as possibly carcinogenic. Here, we briefly describe current state-of-the-art strategies for analyzing and understanding genomic influences of engineered nanomaterial exposure, including the selected focus on lung disease, and strategies for using mechanistic knowledge to predict and prevent adverse outcome.
- 1 April 2018
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 15 (Supplement) , S91-S97
Toxic and Genomic Influences of Inhaled Nanomaterials as a Basis for Predicting Adverse Outcome
An immense variety of different types of engineered nanomaterials are currently being developed and increasingly applied to consumer products. Importantly, engineered nanomaterials may pose unexplored adverse health effects because of their small size. Particularly in occupational settings, the dustiness of certain engineered nanomaterials involves risk of inhalation and influences on lung function. These facts call for quick and cost-effective safety testing practices, such as that obtained through multiparametric high-throughput screening using cultured human lung cells. The predictive value of such in vitro–based testing depends partly on the effectiveness of coverage of the mechanisms underlying toxicity effects. The concept of adverse outcome pathways covers the array of causative effects starting from a molecular initiating event via cellular-, organ-, individual-, and population-level effects. Screening for adverse outcome pathway–related effects that drive the eventual toxic outcome provides a good basis for developing predictive testing methods and data-driven integrated testing strategies for hazard and risk assessment. Temporal and inherited genomic changes are likely to drive many adverse responses to engineered nanomaterials, such as multiwalled carbon nanotubes, of which one specific form has recently been evaluated as possibly carcinogenic. Here, we briefly describe current state-of-the-art strategies for analyzing and understanding genomic influences of engineered nanomaterial exposure, including the selected focus on lung disease, and strategies for using mechanistic knowledge to predict and prevent adverse outcome.
- Open Access
- 23 May 2014
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 115 (1) , 50-58
Cancer Biology, Toxicology and Alternative Methods Development Go Hand‐in‐Hand
Toxicological research faces the challenge of integrating knowledge from diverse fields and novel technological developments generally in the biological and medical sciences. We discuss herein the fact that the multiple facets of cancer research, including discovery related to mechanisms, treatment and diagnosis, overlap many up and coming interest areas in toxicology, including the need for improved methods and analysis tools. Common to both disciplines, in vitro and in silico methods serve as alternative investigation routes to animal studies. Knowledge on cancer development helps in understanding the relevance of chemical toxicity studies in cell models, and many bioinformatics‐based cancer biomarker discovery tools are also applicable to computational toxicology. Robotics‐aided, cell‐based, high‐throughput screening, microscale immunostaining techniques and gene expression profiling analyses are common tools in cancer research, and when sequentially combined, form a tiered approach to structured safety evaluation of thousands of environmental agents, novel chemicals or engineered nanomaterials. Comprehensive tumour data collections in databases have been translated into clinically useful data, and this concept serves as template for computer‐driven evaluation of toxicity data into meaningful results. Future ‘cancer research‐inspired knowledge management’ of toxicological data will aid the translation of basic discovery results and chemicals‐ and materials‐testing data to information relevant to human health and environmental safety.
- 23 May 2014
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 115 (1) , 50-58
Open AccessCancer Biology, Toxicology and Alternative Methods Development Go Hand‐in‐Hand
Toxicological research faces the challenge of integrating knowledge from diverse fields and novel technological developments generally in the biological and medical sciences. We discuss herein the fact that the multiple facets of cancer research, including discovery related to mechanisms, treatment and diagnosis, overlap many up and coming interest areas in toxicology, including the need for improved methods and analysis tools. Common to both disciplines, in vitro and in silico methods serve as alternative investigation routes to animal studies. Knowledge on cancer development helps in understanding the relevance of chemical toxicity studies in cell models, and many bioinformatics‐based cancer biomarker discovery tools are also applicable to computational toxicology. Robotics‐aided, cell‐based, high‐throughput screening, microscale immunostaining techniques and gene expression profiling analyses are common tools in cancer research, and when sequentially combined, form a tiered approach to structured safety evaluation of thousands of environmental agents, novel chemicals or engineered nanomaterials. Comprehensive tumour data collections in databases have been translated into clinically useful data, and this concept serves as template for computer‐driven evaluation of toxicity data into meaningful results. Future ‘cancer research‐inspired knowledge management’ of toxicological data will aid the translation of basic discovery results and chemicals‐ and materials‐testing data to information relevant to human health and environmental safety.